SWOG clinical trial number
SWOG-8801
A Study of the Sequential Combination of Recombinant Interferon Gamma (rIFN-y) and Recombinant Interleukin-2 (rIL-2) in Patients with Disseminated Malignant Disease
Closed
Phase
Accrual
100%
Published
Abbreviated Title
A Study of the Sequential Combination of Recombinant Interferon Gamma (rIFN-y) and Recombinant Interleukin-2 (rIL-2) in Patients with Disseminated Malignant Disease
Activated
10/01/1988
Closed
01/01/1990
Publication Information Expand/Collapse
1992
A Southwest Oncology Group phase I study of sequential combination of recombinant interferon-y and recombinant interleukin-2 in patients with cancer.
1990
A phase I study of the sequential combination of recombinant gamma-interferon (IFN7) and recombinant interleukin-2 (IL2) in patients with disseminated malignant disease.